Low level Laser Hair Therapy of the scalp has been advocated for years as a way to stimulate the scalp and/or hair to improve hair growth and reduce hair loss. The first FDA trials have been completed and the HairMax LaserComb was approved (2007) to re-grow hair and decrease hair loss. This FDA clearance of the HairMax LaserComb offers an exciting new modality for the promotion of hair growth in men. Until now, the FDA has only approved two other products (topical minoxodil and oral Propecia) as solutions to combat hair loss, a condition that affects approximately 55 million men in the U.S.
 

This gives many hair loss sufferers, previously unable or unwilling to turn to drug-based solutions, new found hope in their battle. Fortunately, treatments using the HairMax LaserComb are easy to administer, requiring only 10 to 15 minutes three times per week. The laser device is convenient to use in the comfort and privacy of your own home.
 

For the FDA submission, Lexington conducted an extensive clinical study in four different locations across the United States. The study concluded that 93% of the participants (ages 30-60) using the HairMax LaserComb had an increase in the number of terminal (thick) hairs. The average number of terminal hairs per square centimeter increased by 19 hairs/cm2 over a six-month period. During the study, there were no reports of serious adverse events. The number and types of adverse events were similar in both the active and placebo groups.
 

Lexington’s clinical study investigating the efficacy of the HairMax LaserComb in females is being conducted and they will be submitting the data to the FDA shortly.

In summary, Dr. Goertz feels that in treating male pattern balding, the most effective medical treatment in men to prevent and slow hair loss is finasteride followed by minoxidil and lastly low light laser therapy in that order. For treatment of female pattern balding both laser therapy and minoxidil are slightly effective adjunctive therapeutic approaches.